AgingResearch.NewsJoin free

Visual evoked potential latency

Biomarker

1 paper1 finding

  • Human trial1

Interventions

1

Bexarotene

downin humans1

1 study

  1. Bexarotene decreases visual evoked potential latency in humans (-0.45 ms per year of age).

    “shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age)”

    Human trialin patients with chronic optic neuropathy

    Remyelination in humans due to a retinoid-X receptor agonist is age-dependent

    Annals of clinical and translational neurologyMay 19, 2022

More on Bexarotene

Latest

Related